杭州奥泰生物技术股份有限公司 关于以集中竞价交易方式回购股份的 回购报告书

Core Viewpoint - The company plans to repurchase its shares using funds raised from its initial public offering, with the aim of reducing its registered capital and enhancing shareholder value [2][36]. Group 1: Share Repurchase Details - The total amount for the share repurchase will be no less than RMB 100 million and no more than RMB 200 million [2]. - The repurchase price will not exceed RMB 85 per share, which is 150% of the average trading price over the last 30 trading days prior to the board's decision [2][14]. - The repurchase will be conducted through centralized bidding [3][9]. Group 2: Implementation Timeline - The repurchase period will last for 12 months from the date the shareholders' meeting approves the plan [4][10]. - If the repurchase amount reaches the upper limit, the plan will be completed early [11]. Group 3: Purpose and Funding - The purpose of the repurchase is to maintain shareholder interests and enhance investor confidence based on the company's future development prospects [7][36]. - The funds for the repurchase will come from the excess funds raised during the company's initial public offering [15][36]. Group 4: Shareholder and Management Plans - As of the announcement date, there are no plans for share reductions by directors, senior management, or major shareholders in the next three to six months [4][18]. - The proposal for the share repurchase was initiated by the company's controlling shareholder and chairman, Gao Fei [19][36]. Group 5: Legal and Regulatory Compliance - The company has complied with relevant laws and regulations regarding the share repurchase process, including notifying creditors as required [7][37]. - The repurchased shares will be legally canceled, thereby reducing the registered capital [20][21].